Analyst Ratings January 27, 2026

RBC Keeps Outperform on Valvoline, Holds $44 Target Amid Breeze Autocare Integration

Analyst house flags conservative EBITDA guidance and projects upside as company folds in 162 Breeze locations

By Marcus Reed VVV
RBC Keeps Outperform on Valvoline, Holds $44 Target Amid Breeze Autocare Integration
VVV

RBC Capital reiterated its Outperform rating on Valvoline (NYSE: VVV) and maintained a $44.00 price target, citing what it views as conservative fiscal 2026 EBITDA guidance as the company integrates Breeze Autocare. RBC projects modest same-store sales growth for the first quarter of fiscal 2026 and expects adjusted EBITDA slightly above consensus. Other broker actions and company developments this week reinforce a broadly positive analyst stance on the stock.

Key Points

  • RBC reaffirms Outperform and a $44.00 price target; InvestingPro fair value suggests Valvoline is undervalued.
  • RBC forecasts Q1 fiscal 2026 system-wide same-store sales growth of 4.9% and adjusted EBITDA of $114.3 million, slightly above consensus.
  • Jefferies and TD Cowen have issued or adjusted Buy ratings and price targets after Valvoline’s acquisition of 162 Breeze Autocare locations; shares are up 14% YTD versus a 1% gain for the S&P 500.

RBC Capital reaffirmed its Outperform rating on Valvoline (NYSE: VVV) and kept a $44.00 price target, according to a research note issued Tuesday. The bank said the target is consistent with InvestingPro fair value calculations that indicate Valvoline appears undervalued, while sell-side analysts maintain a consensus Buy recommendation.

RBC projects system-wide same-store sales for Valvoline in the first quarter of fiscal 2026 will rise 4.9%, in line with consensus estimates. The firm is forecasting adjusted EBITDA of $114.3 million for that period, a touch above the consensus figure of $113.5 million.

In its note, RBC flagged what it described as "significant conservatism" embedded in Valvoline management’s fiscal 2026 EBITDA guidance as the company works through integrating Breeze Autocare. RBC said that conservatism leaves room for the company to potentially raise the lower end of that guidance later in the fiscal year if integration progresses as planned.

RBC’s $44 price target equates to roughly 13 times its calendar year 2026 adjusted EBITDA estimate of $568 million, a figure that sits above consensus EBITDA expectations of $559 million for the same period.

On the market, Valvoline shares have outperformed year-to-date, rising 14% compared with a 1% increase for the S&P 500. At the same time, short interest in Valvoline has climbed to 52-week highs near 10.5%.

Other recent developments cited by brokers include the retirement announcement for Senior Vice President Mary E. Meixelsperger, effective December 29, 2025. Jefferies resumed coverage of Valvoline with a Buy rating and set a $40.00 price target after Valvoline’s acquisition of 162 Breeze Autocare locations; that deal prompted Jefferies to revise its financial projections for the company.

TD Cowen also moved its valuations higher, raising its price target to $38.00 from $37.00 while keeping a Buy rating, citing improving investor sentiment and potential upside to fiscal 2026 estimates. TD Cowen reiterated a Buy rating with a $37.00 target after Valvoline’s Analyst Day and described the company’s updated earnings-per-share guidance as reasonable and possibly conservative.

Collectively, the analyst responses and the company’s acquisition activity have produced a generally constructive tone among brokers covering Valvoline, with upside to fiscal 2026 estimates noted if integration and execution meet expectations.


Summary

RBC retains an Outperform rating and $44.00 target on Valvoline, projecting modest same-store sales growth and adjusted EBITDA slightly above consensus for Q1 fiscal 2026. The firm sees management’s guidance as conservative amid the Breeze Autocare integration, implying potential for upward revisions later in the fiscal year. Other brokers, including Jefferies and TD Cowen, have also expressed Buy ratings and adjusted price targets following the Breeze acquisition and company disclosures.

Key points

  • RBC keeps an Outperform rating and $44.00 target; InvestingPro data indicate Valvoline is undervalued based on Fair Value calculations.
  • RBC projects Q1 fiscal 2026 system-wide same-store sales growth of 4.9% and adjusted EBITDA of $114.3 million, slightly above consensus.
  • Jefferies and TD Cowen have issued or updated Buy ratings and price targets following Valvoline’s acquisition of 162 Breeze Autocare locations; market reaction shows a 14% YTD share gain versus a 1% rise for the S&P 500.

Risks and uncertainties

  • Conservative company guidance - If management’s fiscal 2026 EBITDA guidance remains conservative, it could mask near-term upside but also reflect integration uncertainties; this affects investors and equity market expectations.
  • Integration of Breeze Autocare - Executing on the integration of 162 Breeze locations creates operational risk that could influence service network efficiency and near-term margins, with implications for automotive services and retail sectors.
  • Market positioning and short interest - Elevated short interest near 10.5% introduces potential stock volatility that may impact trading dynamics for the equity.

Risks

  • Management’s fiscal 2026 EBITDA guidance appears conservative, which could reflect integration uncertainty and affect investor expectations.
  • The integration of 162 Breeze Autocare locations carries operational and execution risk that could influence margins and network efficiency in the automotive services sector.
  • High short interest at roughly 10.5% raises the potential for elevated stock volatility, affecting equity market dynamics.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026